On Apr. 6, 2020, RedHill Biopharma announced the first patient with confirmed coronavirus (COVID-19) diagnosis had been dosed with the Company’s proprietary investigational new drug, opaganib (Yelivaﾮ, ABC294640)1, at a leading hospital in Israel.

The treated patient is suffering from respiratory symptoms related to COVID-19 infection. The treatment is administered under a compassionate use program in accordance with the Israeli Ministry of Health guidelines, with additional patients expected to be treated in the coming days.